secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADAPTIN BIO, INC. (APTN)
CIK:        0001938571
Form:       8-K
Filed at:   2026-04-06T23:59:59+00:00
Accession:  0001213900-26-040458
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptin Bio shares approved for OTCQB quotation under ticker APTN
-----------------------------------------------------------------

- Common shares approved for quotation on OTCQB Venture Market; ticker symbol APTN.
- Trading expected to begin within the next 6-8 weeks, pending any material updates.
- CEO notes lead program APTN-101 is expected to begin a Phase 1 first-in-human trial shortly.
- Company develops precision cancer therapeutics targeting brain and difficult-to-reach tissues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938571/000121390026040458/0001213900-26-040458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938571/000121390026040458/ea0285223-8k_adaptin.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-040458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer